OPEN END TURBO LONG - ZEALAND PHARMA | Real-time Bid/Ask 11:52:53 2024-05-21 am EDT | ||
| 1.4 EUR / 1.49 EUR | +41.67% |
|
| Current month | -29.17% | ||
| 1 month | +13.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 1.4 | +37.25% |
| 24-05-20 | 1.02 | -4.67% |
| 24-05-17 | 1.07 | -9.32% |
| 24-05-16 | 1.18 | -29.76% |
| 24-05-15 | 1.68 | +18.31% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 11:48 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG2C1F |
| ISIN | DE000MG2C1F9 |
| Date issued | 2024-04-15 |
| Strike | 529.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.94 € |
|---|---|
| Lowest since issue | 0.68 € |
| Spread | 0.09 € |
| Spread % | 6.04% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
600
DKK
Average target price
785.6
DKK
Spread / Average Target
+30.93%
- Stock Market
- Certificates
- Certificat
